Bispecific Antibody Market By Product (Blinatumomab, Emicizumab, Others), By Applications (Cancer, Hemophilia, Others), By End User (Hospitals, Cancer Center, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Bispecific Antibody Market

Bispecific antibodies bind to two different epitopes, or antigens at the same time. This dual action principle makes bispecific antibodies an interesting approach to improving target specificity by binding two antigens on the same cell. They are created by combining the binding regions of two different antibodies or by engineering a single antibody with two specificities. This is achieved through various methods, such as genetic engineering, hybridoma technology, or protein engineering techniques. Bispecific antibodies offer an unprecedented combination of precision, stability and diverse targeting ability that have the potential to revolutionize the way we treat serious diseases.

There are several types of bispecific antibodies such as blinatumomab, emicizumab, and others. Others include elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. Applications of bispecific antibodies include cancer, hemophilia, and others. Others includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer’s disease. End users of bispecific antibodies are hospitals, cancer center, and others. Others include clinic, hemophilia treatment center.

Key factors driving the growth of the bispecific antibody market include rise in prevalence of chronic diseases, increase in number of product approvals for bispecific antibody and rise in the research and development activities. Moreover, increase in number of strategic collaborations and partnerships in bispecific antibody market is anticipated to boost the growth of the market. For instance, in January 2022, ABL, a leading biotech research company of the world, announced the collaboration with SANOFI SA, a multinational pharmaceutical and healthcare company. This collaboration aims for the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson’s disease is expected to boost the growth of the market.

In addition, in September 2022, Abpro, a biotech company, finalized strategic partnership with Celltrion, a biopharmaceutical company for global development and commercialization of a cancer treatment bispecific antibody. Moreover, in December 2022, Akeso Inc., a biopharmaceutical company, announces collaboration and license agreement for up to $5 billion with Summit therapeutics, a biopharmaceutical company to accelerate global development and commercialization of its breakthrough bispecific antibody, Ivonescimab (PD-1/VEGF). Thus, rise in the number of strategic collaborations and partnerships is anticipated to increase the development of bispecific antibodies and boost the growth of the bispecific antibody market. Moreover, increase in prevalence of hemophilia, rise in awareness among the population regarding treatment of hemophilia and high presence of market players who manufactures bispecific antibody drives the growth of market.

The bispecific antibody market is segmented on the basis of product, application, end user, and region. On the basis of product, the bispecific antibody market is categorized into blinatumomab, emicizumab, and others. Others subsegment includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. On the basis of application, the bispecific antibody market is divided into cancer, hemophilia, and others. Others subsegment includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. On the basis of end user, the bispecific antibody market is divided into hospitals, cancer center, and others. Others subsegment includes research centers and academic institutions.

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players profiled in the study include AbbVie, Pfizer, Portola Pharmaceuticals, Innovent bio, Merus, MacroGenics, Genmab A/S, AstraZeneca, NovImmune S.A., Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Johnson & Johnson. The players in the market have been actively engaged in the adoption various strategies such as acquisition, product launch and expansion to remain competitive and gain advantage over the competitors in the market. For instance, in April 2023, Lonza, a global pharmaceutical, biotech, and nutrition company announced an agreement with ABL Bio, the leading biotech research company of the world focusing on bispecific antibodies for immuno-oncology and neurodegenerative diseases. The collaboration is intended to help in the development and manufacturing of new bispecific antibody product of the company.

Key Market Insights

By product, emicizumab segment was the highest revenue contributor to the market and is estimated to reach $81,150.21 million by 2032, with a CAGR of 34.4%.

By application, the hemophilia will reach to $87,948.9 million by 2032 segment dominated the global market. However, the cancer segment is expected to be the fastest-growing segment with a CAGR of 35.6% during the forecast period.

By end user, the hospitals segment dominated the global market. However, the cancer center segment is expected to be the fastest-growing segment with a CAGR of 35.3% during the forecast period.

Based on region, North America garnered the largest revenue share in 2022, whereas Asia-pacific is anticipated to grow at the highest CAGR of 36.4% during the forecast period

Overview

The bispecific antibody market was valued at $5,508.30 million in 2022 and is estimated to reach $109,374.07 million by 2032, exhibiting a CAGR of 34.8% from 2023 to 2032.

A bispecific antibody, known as bsAb, is an artificial antibody molecule that is engineered for attachment of two separate target antigens at the same time. Traditional antibodies are generally monospecific, which means they are expected to attach to one antigen only. On the other hand, bispecific antibodies have two antigen-binding sites, permitting them to recognize and attach to two distinct targets. The clinical therapeutic effects of BsAbs are superior to those of monoclonal antibodies (MoAbs), with broad applications for tumor immunotherapy and for the treatment of other diseases cancer, inflammation, viral infection, and autoimmune diseases.

The bispecific antibody market growth is driven by high prevalence rate of cancer as well as auto-immune diseases and advancement in biotechnology and antibody engineering for development of bispecific antibody.  In addition, bispecific antibodies have gained attention in the field of oncology. Bispecific antibodies are expected to simultaneously bind to tumor-specific antigens on cancer cells and immune cells, such as T cells. Rise in prevalence of cancer, infectious diseases, and auto-immune diseases are anticipated to drive the growth of the market. For instance, according to American cancer Society, in 2022, estimated number of new cancer cases in the U.S. were around 1,918,030.

Moreover, Bispecific antibodies (bsAbs), with binding specificity for two different target molecules, have recently been developed for a range of autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriasis, and tested in clinical trials. Thus, rise in prevalence of autoimmune diseases is anticipated to drive the growth of the market during the forecast period.  In addition, rise in demand for bispecific antibodies and high response rate for bispecific antibodies in multiple myeloma drives the growth of the market. For instance, according to American Society of Clinical Oncology (ASCO), in 2023, an estimated 35,730 adults (19,860 men and 15,870 women) in the U.S. are expected to be diagnosed with multiple myeloma. As per the same source, an estimated 176,404 people were diagnosed with multiple myeloma in 2020 globally.

Moreover, rise in effectiveness of the bispecific antibody in multiple myeloma boosts the growth of the market. For instance, according to American Association for Cancer Research, in 2023, the patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate.

Moreover, increase in prevalence of breast cancer and rise in demand for bispecific antibodies in treatment of breast cancer is anticipated to drive the growth of the market. For instance, according to the American Cancer Society, in January 2022, an estimated 287,850 new cases of invasive breast cancer were expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive breast cancer. As per the same source, in 2022, there were more than 3.8 million women with a history of breast cancer in the U.S. In addition, rise in effectiveness of bispecific antibodies in breast cancer treatment drives the growth of the market. For instance, triple negative breast cancer (TNBC) is a kind of breast cancer with a poor prognosis and few treatment options. In October 2021, according to National Library of Medicine, researchers tested the anticancer activity of F7AK3, a bispecific antibody that binds both trophoblast cell surface antigen 2 (TROP2) and CD3 to identify innovative and effective therapeutics for TNBC. Thus, rise in R&D for development of bispecific antibodies is anticipated to boost the market growth.

On the other hand, side effects associated with bispecific antibodies such as cytokine release syndrome, infusion-related reactions, organ toxicity, hematological effects, immunogenicity, and others are anticipated to hamper the growth of the market. Moreover, complex manufacturing processes and regulatory challenges are expected to restrain the growth of the market.

However, increase in demand for medical services in developed countries such as the U.S., Canada, and Germany and growth opportunities in emerging markets are expected to create immense growth opportunities for the bispecific antibody market during the forecast period.

The bispecific antibody market is segmented on the basis of product, application, end user, and region. On the basis of product, the market is categorized into blinatumomab, emicizumab, and others. Others subsegment includes elranatamab, mosunetuzumab, glofitamab, and zenocutuzumab. On the basis of application, the market is divided into cancer, hemophilia, and others. Others subsegment includes autoimmune diseases, neovascular age-related macular degeneration, and Alzheimer disease. On the basis of end user, the market is divided into hospitals, cancer center, and others. Others subsegment includes research centers and academic institutions.

On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global bispecific antibody market are AbbVie, Pfizer, Portola Pharmaceuticals, Innovent bio, Merus, MacroGenics, Genmab A/S, AstraZeneca, NovImmune S.A., Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Johnson & Johnson. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand the bispecific antibody market share.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the bispecific antibody market analysis from 2022 to 2032 to identify the prevailing bispecific antibody market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the bispecific antibody market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global bispecific antibody market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ AbbVie In

Scope of Bispecific Antibody Market Report

1.1. Report description

1.2. Key market segments

1.3. Key benefits to the stakeholders

1.4. Research Methodology

1.4.1. Primary research

1.4.2. Secondary research

1.4.3. Analyst tools and models

2.1. CXO Perspective

3.1. Market definition and scope

3.2. Key findings

3.2.1. Top impacting factors

3.2.2. Top investment pockets

3.3. Porter’s five forces analysis

3.3.1. Low bargaining power of suppliers

3.3.2. Low threat of new entrants

3.3.3. Low threat of substitutes

3.3.4. Low intensity of rivalry

3.3.5. Low bargaining power of buyers

3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of chronic diseases

3.4.1.2. Increase in number of product approvals for bispecific antibody

3.4.1.3. Increase in the research and development activities

3.4.2. Restraints

3.4.2.1. Side effects of bispecific antibodies treatment

3.4.3. Opportunities

3.4.3.1. Rise in number of strategic collaborations and partnerships

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market size and forecast

4.2. Blinatumomab

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.3. Emicizumab

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

4.4. Others

4.4.1. Key market trends, growth factors and opportunities

4.4.2. Market size and forecast, by region

4.4.3. Market share analysis by country

5.1. Overview

5.1.1. Market size and forecast

5.2. Cancer

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Hemophilia

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

5.4. Others

5.4.1. Key market trends, growth factors and opportunities

5.4.2. Market size and forecast, by region

5.4.3. Market share analysis by country

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Key market trends, growth factors and opportunities

6.2.2. Market size and forecast, by region

6.2.3. Market share analysis by country

6.3. Cancer Center

6.3.1. Key market trends, growth factors and opportunities

6.3.2. Market size and forecast, by region

6.3.3. Market share analysis by country

6.4. Others

6.4.1. Key market trends, growth factors and opportunities

6.4.2. Market size and forecast, by region

6.4.3. Market share analysis by country

7.1. Overview

7.1.1. Market size and forecast By Region

7.2. North America

7.2.1. Key trends and opportunities

7.2.2. Market size and forecast, by Product

7.2.3. Market size and forecast, by Applications

7.2.4. Market size and forecast, by End User

7.2.5. Market size and forecast, by country

7.2.5.1. U.S.

7.2.5.1.1. Key market trends, growth factors and opportunities

7.2.5.1.2. Market size and forecast, by Product

7.2.5.1.3. Market size and forecast, by Applications

7.2.5.1.4. Market size and forecast, by End User

7.2.5.2. Canada

7.2.5.2.1. Key market trends, growth factors and opportunities

7.2.5.2.2. Market size and forecast, by Product

7.2.5.2.3. Market size and forecast, by Applications

7.2.5.2.4. Market size and forecast, by End User

7.2.5.3. Mexico

7.2.5.3.1. Key market trends, growth factors and opportunities

7.2.5.3.2. Market size and forecast, by Product

7.2.5.3.3. Market size and forecast, by Applications

7.2.5.3.4. Market size and forecast, by End User

7.3. Europe

7.3.1. Key trends and opportunities

7.3.2. Market size and forecast, by Product

7.3.3. Market size and forecast, by Applications

7.3.4. Market size and forecast, by End User

7.3.5. Market size and forecast, by country

7.3.5.1. Germany

7.3.5.1.1. Key market trends, growth factors and opportunities

7.3.5.1.2. Market size and forecast, by Product

7.3.5.1.3. Market size and forecast, by Applications

7.3.5.1.4. Market size and forecast, by End User

7.3.5.2. France

7.3.5.2.1. Key market trends, growth factors and opportunities

7.3.5.2.2. Market size and forecast, by Product

7.3.5.2.3. Market size and forecast, by Applications

7.3.5.2.4. Market size and forecast, by End User

7.3.5.3. UK

7.3.5.3.1. Key market trends, growth factors and opportunities

7.3.5.3.2. Market size and forecast, by Product

7.3.5.3.3. Market size and forecast, by Applications

7.3.5.3.4. Market size and forecast, by End User

7.3.5.4. Italy

7.3.5.4.1. Key market trends, growth factors and opportunities

7.3.5.4.2. Market size and forecast, by Product

7.3.5.4.3. Market size and forecast, by Applications

7.3.5.4.4. Market size and forecast, by End User

7.3.5.5. Rest of Europe

7.3.5.5.1. Key market trends, growth factors and opportunities

7.3.5.5.2. Market size and forecast, by Product

7.3.5.5.3. Market size and forecast, by Applications

7.3.5.5.4. Market size and forecast, by End User

7.4. Asia-Pacific

7.4.1. Key trends and opportunities

7.4.2. Market size and forecast, by Product

7.4.3. Market size and forecast, by Applications

7.4.4. Market size and forecast, by End User

7.4.5. Market size and forecast, by country

7.4.5.1. Japan

7.4.5.1.1. Key market trends, growth factors and opportunities

7.4.5.1.2. Market size and forecast, by Product

7.4.5.1.3. Market size and forecast, by Applications

7.4.5.1.4. Market size and forecast, by End User

7.4.5.2. China

7.4.5.2.1. Key market trends, growth factors and opportunities

7.4.5.2.2. Market size and forecast, by Product

7.4.5.2.3. Market size and forecast, by Applications

7.4.5.2.4. Market size and forecast, by End User

7.4.5.3. India

7.4.5.3.1. Key market trends, growth factors and opportunities

7.4.5.3.2. Market size and forecast, by Product

7.4.5.3.3. Market size and forecast, by Applications

7.4.5.3.4. Market size and forecast, by End User

7.4.5.4. Australia

7.4.5.4.1. Key market trends, growth factors and opportunities

7.4.5.4.2. Market size and forecast, by Product

7.4.5.4.3. Market size and forecast, by Applications

7.4.5.4.4. Market size and forecast, by End User

7.4.5.5. South Korea

7.4.5.5.1. Key market trends, growth factors and opportunities

7.4.5.5.2. Market size and forecast, by Product

7.4.5.5.3. Market size and forecast, by Applications

7.4.5.5.4. Market size and forecast, by End User

7.4.5.6. Rest of Asia-Pacific

7.4.5.6.1. Key market trends, growth factors and opportunities

7.4.5.6.2. Market size and forecast, by Product

7.4.5.6.3. Market size and forecast, by Applications

7.4.5.6.4. Market size and forecast, by End User

7.5. LAMEA

7.5.1. Key trends and opportunities

7.5.2. Market size and forecast, by Product

7.5.3. Market size and forecast, by Applications

7.5.4. Market size and forecast, by End User

7.5.5. Market size and forecast, by country

7.5.5.1. Latin America

7.5.5.1.1. Key market trends, growth factors and opportunities

7.5.5.1.2. Market size and forecast, by Product

7.5.5.1.3. Market size and forecast, by Applications

7.5.5.1.4. Market size and forecast, by End User

7.5.5.2. Middle East

7.5.5.2.1. Key market trends, growth factors and opportunities

7.5.5.2.2. Market size and forecast, by Product

7.5.5.2.3. Market size and forecast, by Applications

7.5.5.2.4. Market size and forecast, by End User

7.5.5.3. Africa

7.5.5.3.1. Key market trends, growth factors and opportunities

7.5.5.3.2. Market size and forecast, by Product

7.5.5.3.3. Market size and forecast, by Applications

7.5.5.3.4. Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Top player positioning, 2022

9.1. Johnson & Johnson

9.1.1. Company overview

9.1.2. Key Executives

9.1.3. Company snapshot

9.1.4. Operating business segments

9.1.5. Product portfolio

9.1.6. Business performance

9.1.7. Key strategic moves and developments

9.2. F. Hoffmann-La Roche Ltd.

9.2.1. Company overview

9.2.2. Key Executives

9.2.3. Company snapshot

9.2.4. Operating business segments

9.2.5. Product portfolio

9.2.6. Business performance

9.3. AbbVie Inc

9.3.1. Company overview

9.3.2. Key Executives

9.3.3. Company snapshot

9.3.4. Operating business segments

9.3.5. Product portfolio

9.3.6. Business performance

9.3.7. Key strategic moves and developments

9.4. Pfizer Ltd

9.4.1. Company overview

9.4.2. Key Executives

9.4.3. Company snapshot

9.4.4. Operating business segments

9.4.5. Product portfolio

9.4.6. Business performance

9.5. AstraZeneca plc

9.5.1. Company overview

9.5.2. Key Executives

9.5.3. Company snapshot

9.5.4. Operating business segments

9.5.5. Product portfolio

9.5.6. Business performance

9.6. Merus

9.6.1. Company overview

9.6.2. Key Executives

9.6.3. Company snapshot

9.6.4. Operating business segments

9.6.5. Product portfolio

9.7. MacroGenics Inc.

9.7.1. Company overview

9.7.2. Key Executives

9.7.3. Company snapshot

9.7.4. Operating business segments

9.7.5. Product portfolio

9.8. Regeneron Pharmaceuticals, Inc.

9.8.1. Company overview

9.8.2. Key Executives

9.8.3. Company snapshot

9.8.4. Operating business segments

9.8.5. Product portfolio

9.8.6. Business performance

9.9. Bristol-Myers Squibb Company

9.9.1. Company overview

9.9.2. Key Executives

9.9.3. Company snapshot

9.9.4. Operating business segments

9.9.5. Product portfolio

9.9.6. Business performance

9.9.7. Key strategic moves and developments

9.10. Amgen Inc.

9.10.1. Company overview

9.10.2. Key Executives

9.10.3. Company snapshot

9.10.4. Operating business segments

9.10.5. Product portfolio

9.10.6. Business performance

9.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. GLOBAL BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 02. BISPECIFIC ANTIBODY MARKET FOR BLINATUMOMAB, BY REGION, 2022-2032 ($MILLION)

TABLE 03. BISPECIFIC ANTIBODY MARKET FOR EMICIZUMAB, BY REGION, 2022-2032 ($MILLION)

TABLE 04. BISPECIFIC ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 05. GLOBAL BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 06. BISPECIFIC ANTIBODY MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)

TABLE 07. BISPECIFIC ANTIBODY MARKET FOR HEMOPHILIA, BY REGION, 2022-2032 ($MILLION)

TABLE 08. BISPECIFIC ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 09. GLOBAL BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 10. BISPECIFIC ANTIBODY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)

TABLE 11. BISPECIFIC ANTIBODY MARKET FOR CANCER CENTER, BY REGION, 2022-2032 ($MILLION)

TABLE 12. BISPECIFIC ANTIBODY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)

TABLE 13. BISPECIFIC ANTIBODY MARKET, BY REGION, 2022-2032 ($MILLION)

TABLE 14. NORTH AMERICA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 15. NORTH AMERICA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 16. NORTH AMERICA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 17. NORTH AMERICA BISPECIFIC ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 18. U.S. BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 19. U.S. BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 20. U.S. BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 21. CANADA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 22. CANADA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 23. CANADA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 24. MEXICO BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 25. MEXICO BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 26. MEXICO BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 27. EUROPE BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 28. EUROPE BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 29. EUROPE BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 30. EUROPE BISPECIFIC ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 31. GERMANY BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 32. GERMANY BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 33. GERMANY BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 34. FRANCE BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 35. FRANCE BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 36. FRANCE BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 37. UK BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 38. UK BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 39. UK BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 40. ITALY BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 41. ITALY BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 42. ITALY BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 43. REST OF EUROPE BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 44. REST OF EUROPE BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 45. REST OF EUROPE BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 46. ASIA-PACIFIC BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 47. ASIA-PACIFIC BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 48. ASIA-PACIFIC BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 49. ASIA-PACIFIC BISPECIFIC ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 50. JAPAN BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 51. JAPAN BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 52. JAPAN BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 53. CHINA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 54. CHINA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 55. CHINA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 56. INDIA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 57. INDIA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 58. INDIA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 59. AUSTRALIA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 60. AUSTRALIA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 61. AUSTRALIA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 62. SOUTH KOREA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 63. SOUTH KOREA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 64. SOUTH KOREA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 65. REST OF ASIA-PACIFIC BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 66. REST OF ASIA-PACIFIC BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 67. REST OF ASIA-PACIFIC BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 68. LAMEA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 69. LAMEA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 70. LAMEA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 71. LAMEA BISPECIFIC ANTIBODY MARKET, BY COUNTRY, 2022-2032 ($MILLION)

TABLE 72. LATIN AMERICA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 73. LATIN AMERICA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 74. LATIN AMERICA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 75. MIDDLE EAST BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 76. MIDDLE EAST BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 77. MIDDLE EAST BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 78. AFRICA BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022-2032 ($MILLION)

TABLE 79. AFRICA BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022-2032 ($MILLION)

TABLE 80. AFRICA BISPECIFIC ANTIBODY MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 81. JOHNSON & JOHNSON: KEY EXECUTIVES

TABLE 82. JOHNSON & JOHNSON: COMPANY SNAPSHOT

TABLE 83. JOHNSON & JOHNSON: PRODUCT SEGMENTS

TABLE 84. JOHNSON & JOHNSON: PRODUCT PORTFOLIO

TABLE 85. JOHNSON & JOHNSON: KEY STRATERGIES

TABLE 86. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES

TABLE 87. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT

TABLE 88. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS

TABLE 89. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO

TABLE 90. ABBVIE INC: KEY EXECUTIVES

TABLE 91. ABBVIE INC: COMPANY SNAPSHOT

TABLE 92. ABBVIE INC: PRODUCT SEGMENTS

TABLE 93. ABBVIE INC: PRODUCT PORTFOLIO

TABLE 94. ABBVIE INC: KEY STRATERGIES

TABLE 95. PFIZER LTD: KEY EXECUTIVES

TABLE 96. PFIZER LTD: COMPANY SNAPSHOT

TABLE 97. PFIZER LTD: PRODUCT SEGMENTS

TABLE 98. PFIZER LTD: PRODUCT PORTFOLIO

TABLE 99. ASTRAZENECA PLC: KEY EXECUTIVES

TABLE 100. ASTRAZENECA PLC: COMPANY SNAPSHOT

TABLE 101. ASTRAZENECA PLC: PRODUCT SEGMENTS

TABLE 102. ASTRAZENECA PLC: PRODUCT PORTFOLIO

TABLE 103. MERUS: KEY EXECUTIVES

TABLE 104. MERUS: COMPANY SNAPSHOT

TABLE 105. MERUS: PRODUCT SEGMENTS

TABLE 106. MERUS: PRODUCT PORTFOLIO

TABLE 107. MACROGENICS INC.: KEY EXECUTIVES

TABLE 108. MACROGENICS INC.: COMPANY SNAPSHOT

TABLE 109. MACROGENICS INC.: PRODUCT SEGMENTS

TABLE 110. MACROGENICS INC.: PRODUCT PORTFOLIO

TABLE 111. REGENERON PHARMACEUTICALS, INC.: KEY EXECUTIVES

TABLE 112. REGENERON PHARMACEUTICALS, INC.: COMPANY SNAPSHOT

TABLE 113. REGENERON PHARMACEUTICALS, INC.: PRODUCT SEGMENTS

TABLE 114. REGENERON PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES

TABLE 116. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT

TABLE 117. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS

TABLE 118. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

TABLE 119. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES

TABLE 120. AMGEN INC.: KEY EXECUTIVES

TABLE 121. AMGEN INC.: COMPANY SNAPSHOT

TABLE 122. AMGEN INC.: PRODUCT SEGMENTS

TABLE 123. AMGEN INC.: PRODUCT PORTFOLIO

TABLE 124. AMGEN INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. BISPECIFIC ANTIBODY MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF BISPECIFIC ANTIBODY MARKET,2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN BISPECIFIC ANTIBODY MARKET (2023-2032)

FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS

FIGURE 05. LOW THREAT OF NEW ENTRANTS

FIGURE 06. LOW THREAT OF SUBSTITUTES

FIGURE 07. LOW INTENSITY OF RIVALRY

FIGURE 08. LOW BARGAINING POWER OF BUYERS

FIGURE 09. GLOBAL BISPECIFIC ANTIBODY MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 10. BISPECIFIC ANTIBODY MARKET, BY PRODUCT, 2022(%)

FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR BLINATUMOMAB, BY COUNTRY 2022 AND 2032(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR EMICIZUMAB, BY COUNTRY 2022 AND 2032(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 14. BISPECIFIC ANTIBODY MARKET, BY APPLICATIONS, 2022(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR HEMOPHILIA, BY COUNTRY 2022 AND 2032(%)

FIGURE 17. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 18. BISPECIFIC ANTIBODY MARKET, BY END USER, 2022(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)

FIGURE 20. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR CANCER CENTER, BY COUNTRY 2022 AND 2032(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BISPECIFIC ANTIBODY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)

FIGURE 22. BISPECIFIC ANTIBODY MARKET BY REGION, 2022(%)

FIGURE 23. U.S. BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 24. CANADA BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 25. MEXICO BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 26. GERMANY BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 27. FRANCE BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 28. UK BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 29. ITALY BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 30. REST OF EUROPE BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 31. JAPAN BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 32. CHINA BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 33. INDIA BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 34. AUSTRALIA BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 35. SOUTH KOREA BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 36. REST OF ASIA-PACIFIC BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 37. LATIN AMERICA BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 38. MIDDLE EAST BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 39. AFRICA BISPECIFIC ANTIBODY MARKET, 2022-2032 ($MILLION)

FIGURE 40. TOP WINNING STRATEGIES, BY YEAR

FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 43. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 44. COMPETITIVE DASHBOARD

FIGURE 45. COMPETITIVE HEATMAP: BISPECIFIC ANTIBODY MARKET

FIGURE 46. TOP PLAYER POSITIONING, 2022

FIGURE 47. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)

FIGURE 48. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 49. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 50. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 52. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 53. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

FIGURE 54. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 55. PFIZER LTD: SALES REVENUE, 2020-2022 ($MILLION)

FIGURE 56. PFIZER LTD: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 57. PFIZER LTD: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 58. ASTRAZENECA PLC: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 59. ASTRAZENECA PLC: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 60. REGENERON PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 61. BRISTOL-MYERS SQUIBB COMPANY: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 62. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 63. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)

FIGURE 64. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)

FIGURE 65. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%